![](https://endpts.com/wp-content/uploads/2019/01/Sandra-Horning-endpts-tile-Jeff-Rumans-JPM19.jpg)
Roche pulls another major piece out of the wobbly Alzheimer's jenga, shuttering crenezumab PhIIIs
When AC Immune announced two years ago that its partners at Genentech is launching a second Phase III for its Alzheimer’s drug, CEO Andrew Pfeifer touted crenezumab as a “distinct” hope amid disappointing results of other anti-amyloid beta therapies, given at higher doses and targeting earlier stages of the disease.
Today crenezumab has become a big disappointment itself — marking another prominent failure in a frustration-prone field.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.